ADMET considerations for phosphodiesterase-5 inhibitors

Author： Rezvanfar Mohammad Amin   Rahimi Hamid Reza   Abdollahi Mohammad  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.8, Iss.10, 2012-10, pp. : 1231-1245

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular Effects of Phosphodiesterase 5 Inhibitors

By  

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3485-3494

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase 5 inhibitors and erectile dysfunction

By Sandner Peter   Svenstrup Niels   Tinel Hanna   Haning Helmut   Bischoff Erwin  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 1, 2008-01 ,pp. : 21-33

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase-5 Inhibitors: Future Perspectives

By  

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3540-3551

Bentham Science Publishers

Access to resources Recommend Favorite

Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors

By Kloner Robert A   Comstock Gary   Levine Laurence A   Tiger Steven   Stecher Vera J  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2297-2313

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

By  

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite